U.S. markets closed

Misonix, Inc. (MSON)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.37+0.33 (+2.35%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close14.04
Open13.92
Bid12.00 x 900
Ask19.80 x 1100
Day's Range13.92 - 14.48
52 Week Range6.71 - 22.50
Volume58,646
Avg. Volume106,035
Market Cap249.488M
Beta (5Y Monthly)1.20
PE Ratio (TTM)N/A
EPS (TTM)-0.88
Earnings DateSep 03, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Misonix to Report Fiscal 2020 Fourth Quarter Financial Results and Host Conference Call and Webcast on September 3

    FARMINGDALE, N.Y., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, announced today that it will report its fiscal 2020 fourth quarter financial results after the market closes on Thursday, September 3, 2020. The Company will host a conference call and webcast at 4:30 p.m. ET that day to review the results. Both the call and webcast are open to the general public. On July 10, 2020, Misonix reported preliminary unaudited fiscal 2020 fourth quarter revenue of approximately $13.5 million and full year revenue of approximately $62.3 million. At June 30, 2020, the Company had approximately $38 million in cash. For additional information and financial disclosures please see the press release dated July 10, 2020 and current reports on Form 8-K.To access the conference call on September 3, 2020, interested parties may dial 800-437-2398 (domestic) or 323-289-6576 (international) conference ID 8353775. Participants may also listen to a live webcast of the call through the “Events and Presentations” section under “Investor Relations” on Misonix’s website at www.misonix.com. A webcast replay will be available for 30 days following the live event at www.misonix.com.Please call five minutes in advance to ensure that you are connected. Questions and answers will be taken only from participants on the conference call. For the webcast, please allow 15 minutes to register, download and install any necessary software.About Misonix, Inc. Misonix, Inc. (Nasdaq: MSON) designs, manufactures and markets minimally invasive ultrasonic medical devices used for precise bone sculpting, removal of soft and hard tumors and tissue debridement, primarily in the areas of neurosurgery, orthopedic surgery, plastic surgery, wound care and maxillo-facial surgery. The Company combined its SonicOne wound debridement application with its recently acquired TheraSkin product, a leading cellular skin substitute indicated for all wound treatments. The Company’s sales force operates as two divisions, Surgical (Neuro and Spine Applications) and Wound. At Misonix, Better Matters to us. That is why throughout the Company’s history, Misonix has maintained its commitment to medical technology innovation and the development of products that radically improve patient outcomes. Additional information is available on the Company's web site at www.misonix.com.    Contact:    Joe Dwyer   Norberto Aja, Jennifer Neuman Chief Financial Officer   JCIR Misonix, Inc.   212-835-8500 or mson@jcir.com  631-927-9113

  • GlobeNewswire

    Misonix to Present at the 40th Annual Canaccord Genuity Growth Conference

    FARMINGDALE, N.Y., July 30, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it will be participating in the 40th Annual Canaccord Genuity Growth Conference. Misonix Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Misonix Chief Financial Officer, will be making a virtual company presentation on Wednesday, August 12th at 10:30 a.m. ET. Management will also be available to speak with institutional investors in one-on-one virtual meetings throughout the day on August 12th and 13th. If you have questions about Misonix or are interested in conducting a conference call or meeting with management, please contact the Company’s investor relations firm, JCIR, at (212) 835-8500 or via email at mson@jcir.com.About Misonix, Inc. Misonix, Inc. (Nasdaq: MSON) designs, manufactures and markets minimally invasive ultrasonic medical devices used for precise bone sculpting, removal of soft and hard tumors and tissue debridement, primarily in the areas of neurosurgery, orthopedic surgery, plastic surgery, wound care and maxillo-facial surgery. The Company combined its SonicOne wound debridement application with its recently acquired TheraSkin product, a leading cellular skin substitute indicated for all wound treatments. The Company’s sales force operates as two divisions, Surgical (Neuro and Spine Applications) and Wound. At Misonix, Better Matters to us. That is why throughout the Company’s history, Misonix has maintained its commitment to medical technology innovation and the development of products that radically improve patient outcomes. Additional information is available on the Company's web site at www.misonix.com.Contact:    Joe Dwyer                                                                                                Chief Financial Officer                                                                                         Misonix, Inc.                                                                                             631-927-9113Norberto Aja, Jennifer Neuman JCIR 212-835-8500 or mson@jcir.com

  • What Percentage Of Misonix, Inc. (NASDAQ:MSON) Shares Do Insiders Own?
    Simply Wall St.

    What Percentage Of Misonix, Inc. (NASDAQ:MSON) Shares Do Insiders Own?

    If you want to know who really controls Misonix, Inc. (NASDAQ:MSON), then you'll have to look at the makeup of its...